Schering-Plough CEO Fred Hassan: An Interview With “The Pink Sheet” DAILY (Part 3 of 3)
This article was originally published in The Pink Sheet Daily
Executive Summary
Hassan discusses Schering’s late-stage pipeline, including the protease inhibitor boceprevir for hepatitis C and SCH 530348, a thrombin receptor agonist intended as an add-on to Plavix therapy.
You may also be interested in...
Schering-Plough’s Low AE Profile For Boceprevir Phase II Could Be Advantage Over Vertex’s Telaprevir In HCV Race
Vertex tells “The Pink Sheet” DAILY that VX-950 has more robust data, including new numbers scheduled for release at a major medical meeting next month.
Schering-Plough’s Low AE Profile For Boceprevir Phase II Could Be Advantage Over Vertex’s Telaprevir In HCV Race
Vertex tells “The Pink Sheet” DAILY that VX-950 has more robust data, including new numbers scheduled for release at a major medical meeting next month.
Schering-Plough’s R&D Spending Surges Ahead Of Sales Gains
The firm’s large number of Phase III products are an expensive opportunity.